Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniases

Parasitology

Volumn 105, Issue S1, 1992, Pages S71-S78

  Berger, B J ^a   Fairlamb, A H ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

chemotherapy; immunochemotherapy; immunosuppression; leishmaniasis; trypanosomiasis

Indexed keywords

ANTIPROTOZOAL AGENT; ANTITRYPANOSOMAL AGENT; EFLORNITHINE;

AFRICAN TRYPANOSOMIASIS; ANIMAL; ANTIBODY PRODUCTION; CELLULAR IMMUNITY; DRUG EFFECT; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGY; LEISHMANIASIS; MOUSE; RAT; REVIEW;

ANIMAL; ANTIBODY FORMATION; ANTIPROTOZOAL AGENTS; EFLORNITHINE; HUMAN; IMMUNITY, CELLULAR; IMMUNOCOMPROMISED HOST; LEISHMANIASIS; MICE; RATS; SUPPORT, NON-U.S. GOV'T; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

EID: 17644432619     PISSN: 00311820     EISSN: 14698161     Source Type: Journal    
DOI: 10.1017/S0031182000075375     Document Type: Article

References (74)

1. Adams, D. O. (1980). Effector mechanisms of cytologically activated macrophages. I. Secretion of neutral proteases and effect of protease inhibitors. Journal of Immunology 124, 286—300.
2. Adinolfi, L. E., Bonventre, P. F., Vander Pas, M. & Epstein, D. A. (1985). Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis. Infection and Immunity 48, 409—416.
3. Allison, A. C. (1978). Macrophage activation and non-specific immunity. International Review of Experimental Pathology 18, 303—346.
4. Avila, J. L., Biondo, F., Monzon, H. & Convit, J. (1982). Cutaneous leishmaniasis in mice: resistance to glucan immunotherapy, either alone or combined with chemotherapy. American Journal of Tropical Medicine and Hygiene 31, 53—59.
5. Bacchi, C. J., Nathan, H. C., Hutner, S. H., McCann, P. P. & Sjoerdsma, A. (1980). Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210, 332–334.
6. Badaro, R., Falcoff, E., Badaro, F. S., Carvalho, E. M., Pedral-Sampaio, D., Barrai, A., Carvalho, J. S., Barral-Netto, M., Brandely, M., Silva, L., Bina, J. C., Teixeira, R., Falcoff, R., Rocha, H., Ho, J. L. & Johnson, W. D. (1990). Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. New England Journal of Medicine 322, 16–21.
7. Berenguer, J., Moreno, S., Cerenado, E., Bernaldo De Quinas, J. C. L., Garica De La Fuente, A. & Bouza, E. (1989). Visceral leishmaniasis in patients infected with human immunodeficiency virus. Annals of Internal Medicine 111, 129–132.
8. Bitonti, A. J., McCann, P. P. & Sjoerdsma, A. (1986). Necessity of antibody response in the treatment of African trypanosomiasis with α-difluoromethyl-ornithine. Biochemical Pharmacology 35, 331–334.
9. Bitonti, A. J., Cross-Doersen, D. E. & McCann, P. P. (1988). Effects of α-difluoromethylornithine on protein synthesis and synthesis of the variant-specific glycoprotein (VSG) in Trypanosoma brucei brucei. Biochemical Journal 250, 295—298.
10. Black, S. J., Murray, M., Shapiro, S. Z., Kaminsky, R., Borowy, N. K., Musanga, R. & Otieno-Omondi, F. (1989). Analysis of Propionibacterium acnes-induced non-specific immunity to Trypanosoma brucei in mice. Parasite Immunology 11, 371—383.
11. Campbell, G. H., Esser, K. M. & Weinbaum, F. I. (1977). Trypanosoma brucei infection in B-cell-deficient mice. Infection and Immunity 18, 434—438.
12. Cantrell, W. (1955). The effects of coritsone and oxophenarsine on Trypanosoma equiperdum infections in the rat. Journal of Infectious Diseases 96, 259–267.
13. Cohn, Z. A. (1978). The activation of mononuclear phagocytes: fact, fancy and future. Journal of Immunology 121, 813–816.
14. Condom, M. J., Clotet, B., Sirera, G., Milla, F. & Foz, M. (1989). Asymptomatic leishmaniasis in the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine 111, 767–768.
15. Croft, S. L. (1988). Recent developments in the chemotherapy of leishmaniasis. Trends in Pharmacological Sciences 9, 376–381.
16. Darji, A., Magez, R. L., Toreele, E., Palacios, J., Sileghem, M., Songa, E. B., Hamers, R. & Baetselier, P. D. (1992). Mechanisms underlying trypanosome-elicited immunosuppression. Annales de la Sociète Beige de Médicine Tropicale 72S, 27–38.
17. Degee, A. L. W., McCann, P. P. & Mansfield, J. M. (1983). Role of antibody in the elimination of trypanosomes after DL-α-difluoromethylornithine chemotherapy. Journal of Parasitology 69, 818—822.
18. Docampo, R. (1990). Sensitivity of parasites to free radical damage by antiparasitic drugs. Chemical-Biological Interactions 73, 1–27.
19. Ehrlich, P. (1909). On the partial functions of the cell. In The Collected Papers of Paul Ehrlich, Vol. 3 (1960). (ed. Himmelweit, F.), pp. 183—194. London: Pergamon Press.
20. Fairlamb, A. H. (1989). Novel biochemical pathways in parasitic protozoa. Parasitology 99, S93-S112.
21. Fairlamb, A. H. (1990). Future prospects for the chemotherapy of human trypanosomiasis. 1. Novel approaches to the chemotherapy of trypanosomiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 84, 613–617.
22. Fairlamb, A. H. & Cerami, A. (1992). Metabolism and functions of trypanothione in the Kinetoplastida. Annual Review of Microbiology 46, 695–729.
23. Ferreira, M. S., Nishioka, S. D. A., Rocha, A., Silva, A. M., Ferreira, R. G., Olivier, W. & Tostes, S. (1991). Acute fatal Trypanosoma cruzi meningoencephalitis in a human immunodeficiency virus-positive hemophiliac patient. American Journal of Tropical Medicine and Hygiene 45, 723—727.
24. Franca, L. C. M., Fleury, R. N., Ramos, H. A., Lemos, S., Melarago, F. R. & Pasternak, J. (1969). Molesta de Chagas cronica associada a leucemia linfatica: ocorrencia de encefalite aguda com alteracao do estado immunitario. Arquivo de Neuro-Psiquiatria 27, 59–66.
25. Frommel (1988). Trypanosoma brucei rhodesiense: Effect of immunosuppression on the efficacy of melarsuprol treatment of infected mice. Experimental Parasitology 67, 364–366.
26. Goodwin, L. G., Green, D. G., Guy, M. W. & Voller, A. (1972). Immunosuppression during trypanosomiasis. British Journal of Experimental Pathology 53, 40–43.
27. Grammiccia, M., Gradoni, L. & Troiani, M. (1992). HIV-Leishmania co-infections in Italy. Isoenzyme characterization of Leishmania causing visceral leishmaniasis in HIV patients. Transactions of the Royal Society of Tropical Medicine and Hygiene 86, 161–163.
28. Haidaris, C. G. & Bonventre, P. F. (1981). Elimination of Leishmania donovani amastigotes by activated macrophages. Infection and Immunity 33, 918—926.
29. Haidaris, C. G. & Bonventre, P. F. (1983). Efficacy of combined immunostimulation and chemotherapy in experimental leishmaniasis. American Journal of Tropical Medicine and Hygiene 32, 286–295.
30. Harel-Bellan, A., Joskowicz, M., Fradelizi, D. & Eisen, H.(1983). Modification of T-cell proliferation and interleukin-2 production in mice infected with Trypanosoma cruzi. Proceedings of the National Academy of Sciences USA 80, 3466–3469.
31. Hawking, F.(1938). Contribution on the mode of action of germanin (Bayer 205). Annals of Tropical Medicine and Parasitology 33, 13–19.
32. Henderson, G. B., Fairlamb, A. H. & Cerami, A. (1987). Trypanothione dependent peroxide metabolism in Crithidia fasciculata and Trypanosoma brucei. Molecular and Biochemical Parasitology 24, 39–45.
33. Hoover, D. L., Nacy, C. A. & Meltzer, M. S. (1985). Human monocyte activation for cytotoxicity against intracellular Leishmania donovani amastigotes: induction of microbicidal activity by interferon-gamma. Cellular Immunology 94, 500–511.
34. Iwobi, M. U., Doenhoff, M. J. & Neal, R. A. (1991). Immune-dependence of chemotherapy of experimental visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 85, 56–57.
35. Kaye, P. M.(1987). Antigen presentation and the response to parasitic infection. Parasitology Today 3, 293–299.
36. Kierszenbaum, F., Wirth, J. J., McCann, P. P. & Sjoerdsma, A. (1987). Impairment of macrophage function by inhibitors of ornithine decarboxylase activity. Infection and Immunity 55, 2461—2464.
37. Kohl, S., Pickering, L. K., Frankel, L. S. & Yaeger, R. G. (1982). Reactivation of Chagas’ disease during therapy of acute lymphocytic leukaemia. Cancer 50, 827–8.
38. Kuhn, R. E.(1981). Immunology of Trypanosoma cruzi infections. In Parasitic Diseases, Vol. 1 (ed. Mansfield, J. M.), pp. 137–166. New York: Marcel Dekker.
39. Lelchuk, R., Cardoni, R. L. & Fuks, A. S. (1977a). Cell mediated immunity in Chagas’ disease: alterations induced by treatment with a trypanocidal drug (nifurtimox). Clinical and Experimental Immunology 30, 434–8.
40. Lelchuk, R., Cardoni, R. L. & Lewis, S. (1977b). Nifurtimox-induced alterations in the cell-mediated immune response to PPD in guinea pigs. Clinical and Experimental Immunology 30, 469–473.
41. Liew, F.W. & Cox, F. E. G. (1990). Non-specific defence mechanism: the role of nitric oxide. Parasitology Today 7, A17-A20.
42. Louis, J. P., Jannin, J., Hengy, C., Moulia-Pelat, J. P., Makuwa, M., Asonganzi, T., Novtoua, L., Fadat, G., Nguerenemo, P., Cattand, P. & Trebrica, A. (1991). Absence d'interrelations epidemiologiques entres 1'infection retrovirale a VIH et al trypanosomiase humaine africaine (THA). Bulletin de la Sociète de Pathologie Exotique 84, 25–29.
43. Mansfield, J. M. (1981). Immunology and immunopathology of African trypanosomiasis. In Parasitic Diseases, Vol. 1 (ed. Mansfield, J. M.), pp. 167–226. New York: Marcel Dekker.
44. Mansfield, J. M. & Wallace, J. H. (1974). Suppression of cell-mediated immunity in experimental African trypanosomiasis. Infection and Immunity 10, 335—339.
45. Metze, K., Lorand-Metze, I., Antonio De Almeida, E. & Lauar De Oraes, S. (1991). Reactivation of Chagas’ myocarditis during therapy of Hodgkin's disease. Tropical and Geographical Medicine 43, 228–230.
46. Montalban, C., Calleja, J. L., Erice, A., Laguna, F., Clotet, B., Odzanczer, D., Covo, J., Mallolas, J., Yebra, M., Gallego, A. & THE COOPERATIVE GROUP FOR THE STUDY OF LEISHMANIASIS IN AIDS (1990). Visceral leishmaniasis in patients infected with human immunodeficiency virus. Journal of Infection 21, 261–270.
47. Morello, A.(1988). The biochemistry of the mode of action of drugs and the detoxification mechanisms in Trypanosoma cruzi. Comparative Biochemistry and Physiology 90C, 1–12.
48. Mott, F.W. (1906). The changes produced in the nervous system by chronic trypanosome infections. Lancet 2, 870.
49. Murray, H. W., Masur, H. & Keithly, J. S. (1982). Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity. Journal of Immunology 129, 344–350.
50. Murray, H. W., Rubin, B. Y. & Rothermel, C. D. (1983). Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. Journal of Clinical Investigations 72, 1506—1570.
51. Murray, H. W., Berman, J. D. & Wright, S. D. (1988). Immunochemotherapy for intracellular Leishmania donovani infection: gamma-interferon plus pentavalent antimony. Journal of Infectious Diseases 157, 973–978.
52. Nathan, C. N., Nogueira, N., Ellis, J. & Cohn, Z. (1979). Activation of macrophages in Vivo and in vitro. Correlation between hydrogen peroxide release and killing of Trypanosoma cruzi. Journal of Experimental Medicine 149, 1056–1068.
53. Nathan, C. F., Murray, H. W., Wiebe, M. E. & Rubin, B. Y. (1983). Identification of interferon-gamma as the lymphokine that activates human microbicidal oxidative metabolism and antimicrobial activity. Journal of Experimental Medicine 158, 670–689.
54. Nogueira, N. & Cohn, Z. A. (1978). Trypanosoma cruzi: in vitro induction of macrophage microbicidal activity. Journal of Experimental Medicine 148, 288–300.
55. North, R.J. (1978). The concept of the activated macrophage. Journal of Immunology 121, 806–809.
56. Osman, A. S., Jennings, F. W. & Holmes, P. H. (1992). The rapid development of drug-resistance by Trypanosoma evansi in immunosuppressed mice. Acta Tropica 50, 249–257.
57. Penketh, P. G., Kennedy, W. P. K., Patton, C. L. & Sartorelli, A. C. (1987). Trypanosomatid hydrogen peroxide metabolism. FEBS Letters 221, 427–431.
58. Pepin, J., Ethier, L., Kazade, C., Milford, F. & Ryder, R. (1992). The impact of human immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire. American Journal of Tropical Medicine and Hygiene 47, 133–140.
59. Peters, B. S., Fish, D., Golden, R., Evans, D. A., Bryceson, A. D. M. & Pinching, A. J. (1990). Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Quarterly Journal of Medicine 77, 1101–1111.
60. Raether, W. (1988). Chemotherapy and other control measures of parasitic diseases in domestic animals and man. In Parasitology in Focus (ed. Melhorn, H.), pp. 739–866. Berlin: Springer-Verlag.
61. Reed, S. G. (1981). Immunology of Leishmania infections. In Parasitic Diseases, Vol. 1 (ed. Mansfield, J. M.), pp. 291—314. New York: Marcel Dekker.
62. Reed, S. G. (1988). In vivo administration of recombinant INF-γ induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. Journal of Immunology 140, 4342–4347.
63. Reed, S. G., Nathan, C. F., Pihl, D. L., Rodricks, P., Shanebeck, K., Conlon, J. & Grabstein, K. H. (1987). Recombinant granulocyte/macrophage colony-stimulating factor activates macrophages to inhibit Trypanosoma cruzi and releases hydrogen peroxide. Comparison with interferon-gamma. Journal of Experimental Medicine 166, 1734—1746.
64. Reiner, N. E. (1987). Parasite accessory cell interactions in murine leishmaniasis. I. Evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani. Journal of Immunology 138, 1919–1925.
65. Reiner, N. E., Ng, W. & Mcmaster, W. R. (1987). Parasite accessory cell interactions in murine leishmaniasis. II. Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products. Journal of Immunology 138, 1926–1932.
66. Reiner, N.E., Ng, W., Ma, T. & Mcmaster, W. R. (1988). Kinetics of gamma-interferon binding and induction of major histocompatibility complex class II mRNA in leishmania-infected macrophages. Proceedings of the National Academy of Sciences USA 85, 4330—4334.
67. Rizzi, M., Arici, C., Bonaccorso, C. & Gavazzini, G. (1988). Visceral leishmaniasis in a patient with human immunodeficiency virus. Transactions of the Royal Society of Tropical Medicine and Hygiene 82, 565.
68. Selim, M. M. (1990). Leishmaniasis. Currently recommended treatment. International Journal of Dermatology 29, 318–321.
69. Sen, H. G., Dutta, B. N. & Ray, H. N. (1955). Effect of splenectomy on ‘Antrycide’ therapy of Trypanosoma evansi infection in rats. Nature 175, 778–779.
70. Sileghem, M., Darji, A. & Betselier, P. D. (1991). In vitro simulation of immunosuppression caused by Trypanosoma brucei. Immunology 73, 246–248.
71. Snyder, D. S. & Unanue, E. R. (1982). Corticosteroids inhibit murine macrophage la expression and interleukin 1 production. Journal of Immunology 129, 1803–1805.
72. Sunkara, P. S., Prakash, N.J., Mayer, G. D. & Sjoerdsma A. (1983). Tumour suppression with a combination of α-difluoromethylornithine and interferon. Science 219, 851–853.
73. Von Jancso, N. & Von Jancso, H. (1934). Wirkungsrmechanismus des Germanins (Bayer 205) bei Trypanosomen. Zentralblatt für Bakteriologie, Parasitenkunde und Infektionskrankheiten 132, 257—292.
74. Von Jancso, N. & Von Jancso, H. (1935). Chemitherapeutische Mittel mit opsinartiger Wirkung. Zeitschrift für Immunitatsforschung 84, 471–505.